Drugs / ALLO-316
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04696731 | Feb 2021 → Jan 2030 expected | clear cell renal carcinoma | Allogene Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2026-07-15 | Allogene Therapeutics | Results Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors allogene.com ↗ |
| 2025-11-06 | Allogene Therapeutics | Results Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update allogene.com ↗
ALLO-316 Achieves Durable Responses in RCC Representing a Potential Breakthrough for CAR T in Solid Tumors; Plans Ongoing to Determine the Next Phase of the Program |
| 2025-06-01 | Allogene Therapeutics | Results Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO allogene.com ↗
A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months |
| 2024-11-07 | Allogene Therapeutics | Results Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update allogene.com ↗
Phase 1 TRAVERSE Trial Demonstrated a Single Infusion of ALLO-316 Can Yield an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) Greater than 50% |
| 2024-11-07 | Allogene Therapeutics | Results Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS allogene.com ↗
Following a single infusion of ALLO-316 in heavily pretreated patients, the trial demonstrated best Overall Response Rate (ORR) of 50% and Confirmed Response Rate of 33% in those patients with CD70 Tumor Proportion Score (TPS) of ≥50% who received DL2. |
| 2024-10-29 | Allogene Therapeutics | Regulatory Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) allogene.com ↗
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-316 for the treatment of adult patients with CD70 positive advanced or metastatic renal cell carcinoma (RCC). |
| 2024-01-04 | Allogene Therapeutics | Results Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma allogene.com ↗
During the careful advancement of the TRAVERSE trial with ALLO-316, the Company has observed remarkable allogeneic CAR T cell expansion and persistence driven by its unique CD70 CAR that allows elimination of alloreactive host lymphocytes. |
| 2023-04-17 | Allogene Therapeutics | Results Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting allogene.com ↗ |
| 2022-11-29 | Allogene Therapeutics | Results Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform allogene.com ↗
Proof-of-Concept for anti-CD70 AlloCAR T in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting Therapy |
| 2022-04-13 | Allogene Therapeutics | Results Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal allogene.com ↗
The current work illustrates that CAR T cells targeting CD70 could be generated in which expression of CD70 CARs was found to mask the cells own CD70 receptors in cis, providing protection from CAR T-mediated fratricide. |
| 2022-03-10 | Allogene Therapeutics | Regulatory Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma allogene.com ↗ |
| 2022-01-10 | Cellectis S.A. | Regulatory Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials cellectis.com ↗ |
| 2020-12-06 | Allogene Therapeutics | Results Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology allogene.com ↗
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced preclinical findings of ALLO-316, an AlloCAR T™ therapy targeting CD70, in models of acute myeloid leukemia (AML). |
All press releases naming this drug 17 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLO-316 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04696731 ↗ |
| Action | Deplete | “ALLO-316 is an allogeneic chimeric antigen receptor (CAR) T-cell product that targets CD70-expressing ccRCC and resists immune rejection by targeting and eliminating patients'...” PMID 42447427 ↗ Jul 2026 |
| Modality | Cell therapy | “ALLO-316 is an allogeneic CAR T cell therapy” NCT04696731 ↗ |
| Target | CD70 | “targeting CD70” NCT04696731 ↗ |